These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

520 related articles for article (PubMed ID: 27589059)

  • 1. MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study.
    Tourbah A; Lebrun-Frenay C; Edan G; Clanet M; Papeix C; Vukusic S; De Sèze J; Debouverie M; Gout O; Clavelou P; Defer G; Laplaud DA; Moreau T; Labauge P; Brochet B; Sedel F; Pelletier J;
    Mult Scler; 2016 Nov; 22(13):1719-1731. PubMed ID: 27589059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Cree BAC; Cutter G; Wolinsky JS; Freedman MS; Comi G; Giovannoni G; Hartung HP; Arnold D; Kuhle J; Block V; Munschauer FE; Sedel F; Lublin FD;
    Lancet Neurol; 2020 Dec; 19(12):988-997. PubMed ID: 33222767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MD1003 (High-Dose Pharmaceutical-Grade Biotin) for the Treatment of Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study.
    Tourbah A; Gout O; Vighetto A; Deburghgraeve V; Pelletier J; Papeix C; Lebrun-Frenay C; Labauge P; Brassat D; Toosy A; Laplaud DA; Outteryck O; Moreau T; Debouverie M; Clavelou P; Heinzlef O; De Sèze J; Defer G; Sedel F; Arndt C
    CNS Drugs; 2018 Jul; 32(7):661-672. PubMed ID: 29808469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacodynamics of MD1003 (high-dose biotin) in the treatment of progressive multiple sclerosis.
    Peyro Saint Paul L; Debruyne D; Bernard D; Mock DM; Defer GL
    Expert Opin Drug Metab Toxicol; 2016; 12(3):327-44. PubMed ID: 26699811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.
    Wolinsky JS; Arnold DL; Brochet B; Hartung HP; Montalban X; Naismith RT; Manfrini M; Overell J; Koendgen H; Sauter A; Bennett I; Hubeaux S; Kappos L; Hauser SL
    Lancet Neurol; 2020 Dec; 19(12):998-1009. PubMed ID: 33129442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
    Kapoor R; Ho PR; Campbell N; Chang I; Deykin A; Forrestal F; Lucas N; Yu B; Arnold DL; Freedman MS; Goldman MD; Hartung HP; Havrdová EK; Jeffery D; Miller A; Sellebjerg F; Cadavid D; Mikol D; Steiner D;
    Lancet Neurol; 2018 May; 17(5):405-415. PubMed ID: 29545067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
    Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
    Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.
    Lublin F; Miller DH; Freedman MS; Cree BAC; Wolinsky JS; Weiner H; Lubetzki C; Hartung HP; Montalban X; Uitdehaag BMJ; Merschhemke M; Li B; Putzki N; Liu FC; Häring DA; Kappos L;
    Lancet; 2016 Mar; 387(10023):1075-1084. PubMed ID: 26827074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose pharmaceutical grade biotin (MD1003) in amyotrophic lateral sclerosis: A pilot study.
    Juntas-Morales R; Pageot N; Bendarraz A; Alphandéry S; Sedel F; Seigle S; Camu W
    EClinicalMedicine; 2020 Feb; 19():100254. PubMed ID: 32140672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarkers of treatment response in patients with progressive multiple sclerosis treated with high-dose pharmaceutical-grade biotin (MD1003).
    Collongues N; Kuhle J; Tsagkas C; Lamy J; Meyer N; Barro C; Parmar K; Amann M; Wuerfel J; Kappos L; Moreau T; de Seze J
    Brain Behav; 2021 Feb; 11(2):e01998. PubMed ID: 33314801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High dose biotin as treatment for progressive multiple sclerosis.
    Birnbaum G; Stulc J
    Mult Scler Relat Disord; 2017 Nov; 18():141-143. PubMed ID: 29141796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial.
    Zajicek J; Ball S; Wright D; Vickery J; Nunn A; Miller D; Cano MG; McManus D; Mallik S; Hobart J;
    Lancet Neurol; 2013 Sep; 12(9):857-865. PubMed ID: 23856559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial.
    Chataway J; De Angelis F; Connick P; Parker RA; Plantone D; Doshi A; John N; Stutters J; MacManus D; Prados Carrasco F; Barkhof F; Ourselin S; Braisher M; Ross M; Cranswick G; Pavitt SH; Giovannoni G; Gandini Wheeler-Kingshott CA; Hawkins C; Sharrack B; Bastow R; Weir CJ; Stallard N; Chandran S;
    Lancet Neurol; 2020 Mar; 19(3):214-225. PubMed ID: 31981516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High doses of biotin in chronic progressive multiple sclerosis: a pilot study.
    Sedel F; Papeix C; Bellanger A; Touitou V; Lebrun-Frenay C; Galanaud D; Gout O; Lyon-Caen O; Tourbah A
    Mult Scler Relat Disord; 2015 Mar; 4(2):159-69. PubMed ID: 25787192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of andrographolide in not active progressive multiple sclerosis: a prospective exploratory double-blind, parallel-group, randomized, placebo-controlled trial.
    Ciampi E; Uribe-San-Martin R; Cárcamo C; Cruz JP; Reyes A; Reyes D; Pinto C; Vásquez M; Burgos RA; Hancke J
    BMC Neurol; 2020 May; 20(1):173. PubMed ID: 32380977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.
    Kappos L; Bar-Or A; Cree BAC; Fox RJ; Giovannoni G; Gold R; Vermersch P; Arnold DL; Arnould S; Scherz T; Wolf C; Wallström E; Dahlke F;
    Lancet; 2018 Mar; 391(10127):1263-1273. PubMed ID: 29576505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis: A Randomized, Phase 3, Clinical Trial.
    Vermersch P; Brieva-Ruiz L; Fox RJ; Paul F; Ramio-Torrenta L; Schwab M; Moussy A; Mansfield C; Hermine O; Maciejowski M;
    Neurol Neuroimmunol Neuroinflamm; 2022 May; 9(3):. PubMed ID: 35190477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe transient myopathy in a patient with progressive multiple sclerosis and high-dose biotin.
    Maillart E; Mochel F; Acquaviva C; Maisonobe T; Stankoff B
    Neurology; 2019 May; 92(22):1060-1062. PubMed ID: 31028130
    [No Abstract]   [Full Text] [Related]  

  • 20. Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial.
    Cadavid D; Mellion M; Hupperts R; Edwards KR; Calabresi PA; Drulović J; Giovannoni G; Hartung HP; Arnold DL; Fisher E; Rudick R; Mi S; Chai Y; Li J; Zhang Y; Cheng W; Xu L; Zhu B; Green SM; Chang I; Deykin A; Sheikh SI;
    Lancet Neurol; 2019 Sep; 18(9):845-856. PubMed ID: 31285147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.